BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 35381746)

  • 1. Induction plus adjuvant chemotherapy, combined treatment with nimotuzumab, and intensity-modulated radiation therapy for N3 stage nasopharyngeal carcinoma: A pilot study.
    Zhou L; Lin J; Chen J; Zhang S
    J Cancer Res Ther; 2021 Dec; 17(7):1730-1735. PubMed ID: 35381746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label, single-arm phase II clinical study of induction chemotherapy and sequential Nimotuzumab combined with concurrent chemoradiotherapy in N3M0 stage nasopharyngeal carcinoma.
    Zhang S; Huang X; Zhou L; Wu G; Lin J; Yang S; Chen J; Lin S
    J BUON; 2018; 23(6):1656-1661. PubMed ID: 30610791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Use of Nimotuzumab in Combination With Intensity-Modulated Radiotherapy and Chemotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Experience of a Single Institution.
    Fangzheng W; Chuner J; Zhiming Y; Tongxin L; Fengqin Y; Lei W; Bin L; Fujun H; Ming C; Weifeng Q; Zhenfu F
    Oncol Res; 2018 Mar; 26(2):277-287. PubMed ID: 29046165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
    Li PJ; Mo HY; Luo DH; Hu WH; Jin T
    Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
    Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
    Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of concurrent chemoradiotherapy combined with nimotuzumab for low-risk T4 stage nasopharyngeal carcinoma: A pilot study.
    Zhang S; Huang X; Zhou L; Lin S
    Medicine (Baltimore); 2018 Sep; 97(38):e12503. PubMed ID: 30235761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma.
    You R; Sun R; Hua YJ; Li CF; Li JB; Zou X; Yang Q; Liu YP; Zhang YN; Yu T; Cao JY; Zhang MX; Jiang R; Mo HY; Guo L; Cao KJ; Lin AH; Qian CN; Sun Y; Ma J; Chen MY
    Int J Cancer; 2017 Sep; 141(6):1265-1276. PubMed ID: 28577306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Wei Z; Zhang Z; Luo J; Li N; Peng X
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study.
    Lu Y; Chen D; Liang J; Gao J; Luo Z; Wang R; Liu W; Huang C; Ning X; Liu M; Huang H
    BMC Cancer; 2019 Dec; 19(1):1262. PubMed ID: 31888551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the efficacy between concurrent chemoradiotherapy with or without adjuvant chemotherapy for stage II nasopharyngeal carcinoma.
    Chen J; Liu T; Sun Q; Jin T
    Medicine (Baltimore); 2020 Jul; 99(29):e20443. PubMed ID: 32702809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective Analysis of the Survival Benefit of Induction Chemotherapy in Stage IVa-b Nasopharyngeal Carcinoma.
    Lan XW; Zou XB; Xiao Y; Tang J; OuYang PY; Su Z; Xie FY
    PLoS One; 2016; 11(8):e0160758. PubMed ID: 27509025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experience with combination of cetuximab plus intensity-modulated radiotherapy with or without chemotherapy for locoregionally advanced nasopharyngeal carcinoma.
    Niu X; Hu C; Kong L
    J Cancer Res Clin Oncol; 2013 Jun; 139(6):1063-71. PubMed ID: 23525586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results of a phase II study of gemcitabine and cisplatin chemotherapy combined with intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Wu M; Ou D; He X; Hu C
    Oral Oncol; 2017 Oct; 73():118-123. PubMed ID: 28939063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma.
    Zhong Q; Zhu X; Li L; Qu S; Liang Z; Zeng F; Pan X
    Oncotarget; 2017 Jun; 8(24):39683-39694. PubMed ID: 28147309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials.
    Kong L; Zhang Y; Hu C; Guo Y; Lu JJ
    Cancer; 2017 Jun; 123(12):2258-2267. PubMed ID: 28192641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
    Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
    Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IMRT combined with S-1 concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a prospective phase II study.
    Lv T; Wang Y; Ou D; Liu P; Qin S; Liu L; Lou P; Wang X
    Invest New Drugs; 2019 Apr; 37(2):352-359. PubMed ID: 30617703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance chemotherapy using S-1 following definitive chemoradiotherapy in patients with N3 nasopharyngeal carcinoma.
    Zong J; Xu H; Chen B; Guo Q; Xu Y; Chen C; Weng Y; Zheng W; Pan J; Lin S
    Radiat Oncol; 2019 Oct; 14(1):182. PubMed ID: 31640719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial.
    Tang LL; Guo R; Zhang N; Deng B; Chen L; Cheng ZB; Huang J; Hu WH; Huang SH; Luo WJ; Liang JH; Zheng YM; Zhang F; Mao YP; Li WF; Zhou GQ; Liu X; Chen YP; Xu C; Lin L; Liu Q; Du XJ; Zhang Y; Sun Y; Ma J
    JAMA; 2022 Aug; 328(8):728-736. PubMed ID: 35997729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study.
    Su Z; Mao YP; Tang J; Lan XW; OuYang PY; Xie FY
    Tumour Biol; 2016 Apr; 37(4):4429-38. PubMed ID: 26499947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.